Digitalis by digitalis, therefore, the second-choice drug lidocaine is more commonly used. Digoxigenin (DIG) is a steroid found exclusively in the flowers and leaves of the plants "D. purpurea" and "D. lanata". It is used as a molecular probe to detect DNA or RNA. It can easily be attached to nucleotides by chemical modifications. DIG molecules are often linked to uridine nucleotides; DIG-labelled uridine (DIG-U) can then be incorporated into RNA probes via "in vitro" transcription. Once hybridisation occurs "in situ", RNA probes with the incorporated DIG-U can be detected with anti-DIG antibodies that are conjugated to alkaline phosphatase. To reveal
New Drug Application Review should complete within 6 months. The decision comes in a "Complete Response Letter". Biologics, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a Biologic License Application (BLA), rather than an NDA. The manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process. Generic drugs that have already been approved via an NDA submitted by another maker are approved via an Abbreviated New Drug Application (ANDA), which does not require all of the clinical trials normally required for a new drug